Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The prospective Austrian hypertrophic cardiomyopathy registry - design, methods and results of the run-in period.

Heart failure reviews·2026

Same author

Walking capacity and venous claudication after deep vein thrombosis: prospective follow-up, risk factors, and quality of life.

Journal of thrombosis and haemostasis : JTH·2025

Same author

Optoacoustic imaging in lower extremity revascularization: A novel technique to assess perioperative muscle perfusion.

Photoacoustics·2025

Same author

Pain Relief During Recanalization of Chronic Femoropopliteal Artery Occlusions With Use of a Crossing Catheter.

JACC. Case reports·2025

Same author

Correction to: Diagnosis and treatment of iron deficiency in chronic heart failure.

Wiener klinische Wochenschrift·2025

Same author

Acute Kidney Injury After Peripheral Interventions Using Carbon Dioxide Angiography-Risk Factors Beyond Iodinated Contrast Media.

Life (Basel, Switzerland)·2025

Search research articles

Related Experiment Video

Updated: May 30, 2026

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients

Deddo Moertl¹, Rudolf Berger, Alexandra Hammer

¹Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. deddo.moertl@meduniwien.ac.at

Thrombosis and Haemostasis

|July 30, 2011

Summary

Omega-3 polyunsaturated fatty acids (n3-PUFA) reduce platelet activation and tissue factor (TF) in chronic heart failure (CHF) patients. Higher doses also offer anti-inflammatory benefits, improving outcomes in severe CHF.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: May 30, 2026

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

Cardiology
Biochemistry
Pharmacology

Background:

Chronic heart failure (CHF) involves neuroendocrine and inflammatory pathways, promoting a prothrombotic state.
Omega-3 polyunsaturated fatty acids (n3-PUFA) show mortality benefits in CHF, but mechanisms are unclear.
Investigating n3-PUFA's impact on platelet activation and thrombogenesis in severe CHF is crucial.

Purpose of the Study:

To investigate the effects of n3-PUFA on platelet activation and thrombogenesis markers in severe CHF patients.
To determine the dose-dependent effects of n3-PUFA on these markers.

Main Methods:

Thirty-six patients with severe non-ischaemic CHF received 1g/day or 4 g/day n3-PUFA, or placebo for 12 weeks.
Whole-blood flow cytometry assessed monocyte-platelet aggregates (CD14+/CD42b+) and monocytic tissue factor (TF).
Plasma levels of P-selectin, sCD40L, fibrinogen, prothrombin fragment F1.2, TF, and inflammatory markers were measured.

Main Results:

n3-PUFA significantly reduced monocyte-platelet aggregates dose-dependently.
4 g/day n3-PUFA decreased P-selectin and prothrombin fragment F1.2, and reduced plasma TF and TF+-monocytes dose-dependently.
Higher n3-PUFA dosage showed anti-inflammatory effects, reducing hs interleukin-6 and hsTNF-alpha.

Conclusions:

n3-PUFA treatment in severe CHF patients leads to a dose-dependent decrease in platelet activation and tissue factor.
Higher n3-PUFA dosages provide anti-inflammatory effects, potentially contributing to observed clinical benefits.
These findings elucidate mechanisms for n3-PUFA's efficacy in managing severe chronic heart failure.